Seeking Alpha
18 Feb 2026, 15:02 UTC · 30w ago
Verdict
Headline leans bullish. We score HALO +1.00 across four claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Halozyme projects nearly 100% EPS growth and over 70% EBITDA growth for 2026.
So whatExponential bottom-line growth projections typically trigger significant positive valuation reratings.
More positive than 99% of claims this week
2026 revenue guidance is set between $1.71 billion and $1.81 billion.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
More positive than 97% of claims this week
FY25 royalty revenue increased by 52%, contributing to a total revenue growth of 38% to $1.397 billion.
So whatHigh-margin royalty growth indicates improving profitability and strong partner performance.
More positive than 91% of claims this week
Strategic acquisitions have been implemented to extend IP life and diversify the technology portfolio.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Strong revenue growth, surging royalty income, and highly positive 2026 guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2d ago
+39.7%
Price agrees with the score
$112.45 vs $80.48 close before publication (Feb 17) · not market-adjusted
HALO chart →
